Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOPHYL-SR vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing cyclic AMP levels, and antagonizes adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of asthma,Treatment of chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
300 mg orally every 12 hours, with dosing titrated to achieve serum trough concentrations of 5-15 mcg/m L.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Adults: 8-10 hours (range 3-12); Neonates: 20-30 hours; Smokers: 4-5 hours; Cirrhosis: 30-40 hours. Dose adjustments needed based on half-life variations.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Hepatic via CYP1A2, CYP2E1, and CYP3A4; demethylation and oxidation to inactive metabolites (1-methyluric acid, 3-methylxanthine, 1,3-dimethyluric acid).
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal: ~10% unchanged; Hepatic metabolism (90%) via CYP1A2, 3A4; metabolites (caffeine, 3-methylxanthine) excreted renally. Total clearance predominantly hepatic.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
40-60% primarily to albumin.
55–65% bound to plasma proteins, primarily albumin.
0.3-0.5 L/kg (1.0-1.5 L/kg in neonates). Reflects distribution into total body water; higher in dehydrated states.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral immediate-release: 96-100%; Sustained-release: 90-100% (variable among formulations).
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
No specific GFR-based adjustment required, but serum concentrations should be monitored due to altered clearance. For GFR <10 m L/min, reduce dose by 50% and monitor levels.
No dose adjustment required for renal impairment.
Child-Pugh Class A: reduce dose by 50%; Child-Pugh Class B: reduce dose by 60%; Child-Pugh Class C: reduce dose by 80% and monitor serum concentrations closely.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Initial dose: 5 mg/kg/day orally in 2 divided doses, increasing by 2 mg/kg/day every 3 days to maximum 20 mg/kg/day, with monitoring of serum concentrations.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Start at lower end of dosing range (e.g., 200 mg every 12 hours) and titrate slowly due to reduced hepatic clearance; monitor serum concentrations and adjust to therapeutic trough of 5-15 mcg/m L.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No FDA black box warning.
No FDA black box warning exists for this drug.
Use with caution in patients with cardiac disease (e.g., arrhythmias), seizure disorders, peptic ulcer disease, hepatic impairment, and in elderly patients. Monitor serum theophylline levels to avoid toxicity.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or any component of the formulation; active peptic ulcer disease; seizure disorder (unless appropriately controlled with anticonvulsants).
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid large amounts of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase adverse effects. Charcoal-broiled foods can increase clearance, potentially decreasing effectiveness. High-carbohydrate/low-protein diets may increase theophylline levels. St. John's wort may decrease theophylline levels.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
FDA Pregnancy Category C. First trimester: No increased risk of major malformations reported in humans; animal studies show fetal harm at high doses. Second trimester: Potential for maternal tachycardia and uterine relaxation, not teratogenic. Third trimester: Risk of neonatal apnea, bradycardia, and jitteriness at birth if maternal levels are supratherapeutic; no structural anomalies.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Excreted into breast milk; M/P ratio approximately 0.6-0.7. Infant dose ~1-10% of maternal weight-adjusted dose; monitor infant for irritability or insomnia. AAP considers compatible with breastfeeding with caution.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Increased clearance and volume of distribution in pregnancy; dose may need to be increased by 20-30% in second and third trimesters. Monitor levels and adjust based on clinical response and trough concentrations.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Theophylline has a narrow therapeutic index (10-20 mcg/m L). Monitor levels due to significant interindividual pharmacokinetic variability. Smoking induces metabolism; dose adjustments needed when starting/stopping smoking. Avoid in tachyarrhythmias, seizure disorders, or peptic ulcer disease. Cimetidine, ciprofloxacin, and erythromycin increase theophylline levels. Convert between immediate-release and sustained-release formulations cautiously. Use with caution in heart failure, liver disease, and elderly patients due to reduced clearance.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take exactly as prescribed; do not crush or chew sustained-release tablets.,Do not change brands or formulations without consulting your doctor.,Avoid large amounts of caffeine (coffee, tea, cola) as it may increase side effects.,Report symptoms of toxicity: persistent nausea/vomiting, insomnia, tremors, seizures, or rapid/irregular heartbeat.,If you smoke, inform your doctor, as dose adjustments may be needed.,Keep all appointments for blood level monitoring.,Do not stop abruptly; may cause rebound bronchospasm.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOPHYL-SR vs AEROLATE SR, answered by our medical review team.
THEOPHYL-SR is a Bronchodilator that works by Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing cyclic AMP levels, and antagonizes adenosine receptors, leading to bronchodilation and anti-inflammatory effects.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOPHYL-SR and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOPHYL-SR is: 300 mg orally every 12 hours, with dosing titrated to achieve serum trough concentrations of 5-15 mcg/m L.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOPHYL-SR and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOPHYL-SR is classified as Category C. FDA Pregnancy Category C. First trimester: No increased risk of major malformations reported in humans; animal studies show fetal harm at high doses. Second trimester: Potential fo. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.